Zeria PharmceuticalZERIA PHARMCEUTICAL CO., LTD.4559東証プライム医薬品FY ending Mar 2026, consolidated, J-GAAP
Out of every ¥100 of sales, about ¥14 is left as operating profit. Revenue changed +2.1% from the prior year, operating profit +1.4%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | 6.7% | 0.48× | 3.2% | 2.51× | 8.0% |
| 2023 | 9.1% | 0.53× | 4.8% | 2.52× | 12.0% |
| 2024 | 10.2% | 0.53× | 5.4% | 2.53× | 13.7% |
| 2025 | 11.4% | 0.56× | 6.4% | 2.45× | 15.7% |
| 2026 | 9.5% | 0.53× | 5.0% | 2.41× | 12.0% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 59,533 | 68,383 | 75,725 | 87,311 | 89,159 |
| Cost of revenue | 17,385 | 18,895 | 20,224 | 23,351 | 23,977 |
| Gross profit | 42,148 | 49,489 | 55,501 | 63,960 | 65,183 |
| SG&A | 35,782 | 40,474 | 45,880 | 51,762 | 52,808 |
| Operating income | 6,366 | 9,015 | 9,622 | 12,198 | 12,374 |
| Pretax income | 5,722 | 7,273 | 9,508 | 12,619 | 11,200 |
| Income tax | 1,747 | 1,066 | 1,813 | 2,651 | 2,783 |
| Net income attributable to owners | 3,961 | 6,196 | 7,731 | 9,936 | 8,455 |
| Operating margin | 10.7% | 13.2% | 12.7% | 14.0% | 13.9% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥11.6B | ¥16.1B | ¥18.6B | ¥23.5B | ¥27.6B |
| Total assets | ¥124.3B | ¥135B | ¥150.5B | ¥159.2B | ¥179.7B |
| Net assets | ¥55.1B | ¥65.7B | ¥79.8B | ¥89.8B | ¥108.6B |
| Share capital | ¥6.59B | ¥6.59B | ¥6.59B | ¥6.59B | ¥6.59B |
| Property, plant and equipment | ¥23.1B | ¥24.6B | ¥26.5B | ¥26.6B | ¥27.6B |
| Intangible assets excluding goodwill | ¥41.2B | ¥41.9B | ¥43.1B | ¥40.4B | ¥39.6B |
| Goodwill | ¥5.83B | ¥5.3B | ¥4.26B | ¥3.62B | ¥3.03B |
| Investment securities | ¥7.01B | ¥6.85B | ¥9.15B | ¥8.87B | ¥10.1B |
| Current assets | ¥41.7B | ¥48.2B | ¥57.8B | ¥69.5B | ¥82.6B |
| Current liabilities | ¥44.2B | ¥47.2B | ¥54.5B | ¥54.4B | ¥55.7B |
| Short-term borrowings | ¥33.8B | ¥34.9B | ¥38.3B | ¥34.3B | ¥33.8B |
| Long-term borrowings | ¥18.4B | ¥14.5B | ¥7.94B | ¥6.87B | ¥5.27B |
| Total liabilities | ¥69.2B | ¥69.4B | ¥70.7B | ¥69.4B | ¥71.1B |
| Non-controlling interests | ¥197.8M | ¥230.8M | ¥206.2M | ¥257.2M | ¥208M |
| Equity attributable to owners of parent | ¥49.5B | ¥53.5B | ¥59.3B | ¥67.2B | ¥73.6B |
| Retained earnings | ¥48.9B | ¥53.5B | ¥59.3B | ¥67.2B | ¥73.5B |
| Treasury stock | -¥17.6B | -¥18.3B | -¥18.3B | -¥18.3B | -¥12.2B |
EDINET (FSA Japan)
有価証券報告書-第72期(2025/04/01-2026/03/31)
EDINET (FSA Japan)
有価証券報告書-第71期(2024/04/01-2025/03/31)
EDINET (FSA Japan)
有価証券報告書-第70期(2023/04/01-2024/03/31)
EDINET (FSA Japan)
有価証券報告書-第69期(2022/04/01-2023/03/31)
EDINET (FSA Japan)
有価証券報告書-第68期(令和3年4月1日-令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書-第67期(令和2年4月1日-令和3年3月31日)
Extracted from XBRL: 53 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.